Antibody Intellectual Property Protection2022-12-13T11:04:24-05:00

Antibody Intellectual Property Protection.

Protection for your Antibody-Based Assets.

Intellectual property (IP) rights are key considerations in the development of novel and innovative antibodies and antibody-based applications. Due to the rapidly changing nature of antibody-based technologies, it is important to co-develop patent strategies alongside any invention. To obtain patent protection, the invention must pass certain requirements including, but not limited to: novelty; inventive step/non-obviousness; and written description and enablement.

As the number of antibody-based therapeutics, diagnostics and reagents continues to increase, so do patent filings corresponding to these products. As a result, IP authorities (ie. USPTO, EPO) place immense scrutiny on antibody-related patent applications during the patent prosecution process. With the help of next generation protein sequencing (NGPS) and proteomics, patent applications can be strengthened with essential data, including the sequence information of the antibody as well as its binding epitope targets and biophysical properties.

Webinar

Alpaca Antibody Showdown – Selecting Specific Monoclonal Antibodies by SPR

Nov 30, 11 am EST

Services for Intellectual Property Protection.

We support the application process in obtaining protection for your IP. Contact Us to discover how we can help with patent protection.

de novo mAb Sequencing

Protect your mAbs and other antibody formats for therapeutic, diagnostic, research applications by obtaining their amino acid sequences and claim their composition of matter for original patent applications.
Explore REmAb

Protecting Antibodies Based on Binding Target

Characterize and specify specific antigenic epitopes for your antibodies as the scope of protection in patent applications.
Explore HDX-MS

Protecting Antibodies Based on Binding Characteristics

Strengthen patent applications with functional data by characterizing specific binding properties of your antibodies.
Explore SPR Analysis

Application Publications.

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

Talk to Our Scientists.

We Have Sequenced 7000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 6000 antibodies and we are eager to help you.